Treatment standard ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 61 | Autoimmune hemolytic anemia | 1 |
61. Autoimmune hemolytic anemia
Clinical trials : 137 / Drugs : 127 - (DrugBank : 55) / Drug target genes : 26 - Drug target pathways : 153
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05089227 (ClinicalTrials.gov) | February 3, 2022 | 11/10/2021 | Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study | Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study | Prolonged Anticoagulation;Venous Thromboembolic Disease;Autoimmune Hemolytic Anemia | Drug: treatment intervention;Drug: treatment standard;Biological: biological assessment | Centre Hospitalier Universitaire Dijon | NULL | Recruiting | 18 Years | N/A | All | 72 | Phase 2 | France |